Last reviewed · How we verify
QLM3004 Concentration 3
QLM3004 Concentration 3 is a unknown Small molecule drug developed by Qilu Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for unknown.
QLM3004 Concentration 3 is a drug that works by inhibiting the activity of a specific molecular target.
QLM3004 Concentration 3 is a drug that works by inhibiting the activity of a specific molecular target. Used for unknown.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | QLM3004 Concentration 3 |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | unknown |
| Target | unknown |
| Modality | Small molecule |
| Therapeutic area | unknown |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of QLM3004 Concentration 3 is not well understood, but it is believed to involve the inhibition of a specific enzyme or receptor. This inhibition leads to a decrease in the production of a certain molecule, which in turn leads to the therapeutic effect of the drug.
Approved indications
- unknown
Common side effects
- unknown
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLM3004 Concentration 3 CI brief — competitive landscape report
- QLM3004 Concentration 3 updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about QLM3004 Concentration 3
What is QLM3004 Concentration 3?
How does QLM3004 Concentration 3 work?
What is QLM3004 Concentration 3 used for?
Who makes QLM3004 Concentration 3?
What drug class is QLM3004 Concentration 3 in?
What development phase is QLM3004 Concentration 3 in?
What are the side effects of QLM3004 Concentration 3?
What does QLM3004 Concentration 3 target?
Related
- Drug class: All unknown drugs
- Target: All drugs targeting unknown
- Manufacturer: Qilu Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in unknown
- Indication: Drugs for unknown
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing